Compare Merck & Co., Inc. (MRK) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Vanguard Short Term Corporate Bond ETF trades at $78.09. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRK | VCSH | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $80.20 |
52-Week Low | $77.60 | $78.08 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $78.14 with minimal daily movement (-0.05%). The technical picture is bearish with moving averages signaling caution, though oversold RSI readings suggest potential near-term support. The ETF maintains a competitive 4.5% dividend yield with a short 2.7-year duration, positioning it defensively against rising rates while offering higher income than treasury alternatives.
While VCSH provides quality short-term corporate bond exposure with minimal interest rate risk, current tight credit spreads limit upside potential. The ETF faces competition from broader bond funds and carries corporate credit risk. Recent analyst downgrades to 'Hold' reflect concerns about entry timing, though institutional investors continue active positioning in the fund.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
